Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL501 in Heavy Drinkers With PTSD
NCT06335407Phase 1Recruiting
- Sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- Start
- Jul 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dexmedetomidine in alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD), sponsored by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance. Primary endpoints: Change in Blood Pressure (Systolic and Diastolic) at 28 days, State Trait Anxiety Inventory at 28 days and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
alcohol use disorder (AUD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06335407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06335407.